Video Article

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization

Robert Welschinger¹, Linda J. Bendall¹

¹Centre for Cancer Research, Westmead Millennium Institute for Medical Research and University of Sydney

Correspondence to: Linda J. Bendall at linda.bendall@sydney.edu.au

URL: <http://www.jove.com/video/52840>

DOI: [doi:10.3791/52840](https://doi.org/10.3791/52840)

Keywords: Cellular Biology, Issue 102, Acute Lymphoblastic Leukemia, Cell cycle, Bromodeoxyuridine, Flow Cytometry, Chemotherapeutic agents, Cell synchronization

Date Published: 8/16/2015

Citation: Welschinger, R., Bendall, L.J. Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization. *J. Vis. Exp.* (102), e52840, doi:10.3791/52840 (2015).

Abstract

This protocol describes a method to permit the tracking of cells through the cell cycle without requiring the cells to be synchronized. Achieving cell synchronization can be difficult for many cell systems. Standard practice is to block cell cycle progression at a specific stage and then release the accumulated cells producing a wave of cells progressing through the cycle in unison. However, some cell types find this block toxic resulting in abnormal cell cycling, or even mass death. Bromodeoxyuridine (BrdU) uptake can be used to track the cell cycle stage of individual cells. Cells incorporate this synthetic thymidine analog, while synthesizing new DNA during S phase. By providing BrdU for a brief period it is possible to mark a pool of cells that were in S phase while the BrdU was present. These cells can then be tracked through the remainder of the cell cycle and into the next round of replication, permitting the duration of the cell cycle phases to be determined without the need to induce a potentially toxic cell cycle block. It is also possible to determine and correlate the expression of both internal and external proteins during subsequent stages of the cell cycle. These can be used to further refine the assignment of cell cycle stage or assess effects on other cellular functions such as checkpoint activation or cell death.

Video Link

The video component of this article can be found at <http://www.jove.com/video/52840/>

Introduction

The assessment of cell cycle features and changes that occur in cells during cell cycle progression is fundamental to understanding many aspects of biology, particularly cancer biology. Many agents in development for the treatment of malignancies have profound effects on cell cycle progression or induce cell death via cell cycle dependent-mechanisms. In order to study cell cycle dynamics or cells in a particular phase of the cell cycle, it is usual to synchronize cells. However synchronization methods can have detrimental effects on the cells being studied, potentially confounding the results obtained.¹ Recently the use of fluorescently tagged proteins that are only present at particular phases of the cell cycle have permitted analysis of cell cycle progression in single cells over time², however the cells to be studied need to be genetically manipulated to express these tagged proteins, limiting their use to systems where this can be readily achieved.

The cell cycle consists of two active phases: the synthesis (S) phase, where DNA is replicated and mitosis (M) where cell division takes place. These phases are separated by three gap phases, G₀, G₁ and G₂. G₀ or quiescence, is a resting phase where the cell has left the cycle, G₁ is where the cells increase in size prior to DNA replication and G₂ where cell growth continues between completion of DNA replication but before cell division. The progression through the cell cycle is controlled by a number of checkpoints. The G₁ checkpoint is activated when environmental conditions are not supportive of DNA synthesis and prevents entry into S phase. The intra-S phase checkpoint or delay can be triggered by DNA damage that may result in stalled replication forks. During G₂ the fidelity of the replicated DNA is confirmed and if damage is detected then the G₂ checkpoint is activated permitting DNA repair prior to cell division. A final checkpoint during mitosis ensures that chromatids have been correctly aligned at the mitotic plate so that cell division can be successfully completed.³ Activation of these checkpoints is commonly used to synchronize cell populations. Cell cycle checkpoints can be activated by a number of factors but in cancer biology the most common is detection of DNA damage. The DNA damage response is initiated by the PI3-kinase-like kinases ataxia telangiectasia and Rad3 related (ATR) and ataxia telangiectasia mutated (ATM) that activate the downstream effector kinases Chk1 and Chk2, respectively.³ A range of events activates Chk1 including stalled replication forks, DNA crosslinks, and ultraviolet radiation damage while Chk2 is primarily activated by double-strand breaks.

The usual method for studying the effect of altered conditions on the length of the cell cycle is to synchronize the cells in a particular phase of the cell cycle.¹ This can be achieved via several methods. Cells can be physically separated based on size, density, side scatter (granularity), and cell surface expression markers. More practically, cells may be synchronized by chemical means. Several agents such as thymidine, hydroxyurea and cytosine arabinoside can be used to inhibit DNA synthesis in the S phase of cell cycle resulting in an accumulation of cells in S phase which continue cycling after the agents are removed. Cells treated with nocodazole, which prevents the formation of the mitotic spindle, arrest with a G₂- or M-phase DNA content. Elimination of serum from the culture medium results in the accumulation of cells at G₀ phase. The re-

addition of the nutrients within the culture serum re-starts the normal cycling of the cells. However, all of these synchronization methods interfere with normal cycling and growth of cells and can result in significant cell death.

Synchronization of acute lymphoblastic leukemia cells is particularly challenging and these cells are not amenable to genetic manipulation. The method described here permits the assessment of cell cycle dynamics and the study of cells in particular phases of the cell cycle without traditional synchronization or genetic modification. This method may also be useful for other cell types where genetic modification and traditional synchronization procedures are not readily achieved. The method is based on the long established use of bromodeoxyuridine (BrdU) incorporation, which has very little impact on the short-term growth and proliferation of cells.⁴ Established BrdU protocols take advantage of the incorporation of BrdU into newly synthesized DNA during S phase. This permanently marks cells as having been in S phase during BrdU exposure. This population can be identified at later time points by staining for BrdU incorporation and thereby act as a synchronized population that can be followed and assessed over time permitting the study of drug effects on cell cycle transit. BrdU needs to be exposed prior to antibody staining, usually achieved following DNase or acid treatment.^{6,7} Using flow cytometry to detect incorporated BrdU enables the inclusion of additional markers. The most important is the use of dyes to measure DNA content, enabling the assessment of cell cycle phase distribution of the cells that were in S phase at the start of the study.⁸ Furthermore additional surface or intracellular antigens can also be studied.⁹ These may relate to cell cycle events such as Ki67 or to seemingly unrelated cell features such as apoptosis markers like cleaved caspase-3. The potential applications are limited by the imagination of the investigator.

Protocol

The protocol described here uses the acute lymphoblastic leukemia cell line NALM6 but can be applied to other cell types.

1. Solutions and Reagents

1. Complete RPMI
 1. Add 56 ml fetal calf serum (FCS) and 5.5 ml of 200 mM L-glutamine to a 500 ml bottle of RPMI-1640 medium.
2. BrdU Stock Solution
 1. Prepare 32.5 mM BrdU (10 mg/ml) in Dulbecco's Phosphate Buffered Saline (DPBS).
3. BrdU Complete RPMI
 1. Add 6.2 μ l of BrdU stock solution to 10 ml of Complete RPMI.
4. DNase Solution
 1. Prepare 1 mg DNase/ml in DPBS.
5. Staining Buffer
 1. Prepare 3% heat-inactivated FCS and 0.09% sodium azide in DPBS.
6. Refer to Materials List for definitions of Fixation Buffer, Permeabilization Buffer and Wash Buffer.

2. Cells

Note: Cells were not cultured for greater than 6 months. This method is directly adaptable to any non-adherent cell line with adjustments to cell density and culture media. Use cells that are growing exponentially at the initiation of the experiment.

1. Maintain NALM6 cells in T-75 culture flasks in Complete RPMI. Perform all steps under sterile conditions using a Class II Biosafety Cabinet.
 1. Maintain NALM6 cells between $1-2 \times 10^6$ cells per ml by splitting the culture thrice weekly.
 2. Incubate at 37 °C in 5% CO₂ in air.

3. Pulse Labeling of Cells with BrdU

CAUTION: Handle BrdU with care as it is a potential mutagen and teratogen.

1. Centrifuge cells at 150 x g for 5 min. Note: Transferring cells into fresh media improves the reproducibility of the results.
2. Perform a cell count and resuspend cells in Complete RPMI at 2×10^6 cells/ml.
3. Dilute cells 1 in 2 with BrdU Complete RPMI producing a final cell concentration of 1×10^6 cells/ml.
4. Incubate at 37 °C in 5% CO₂ for 45 min, then dilute cells 1 in 10 with complete RPMI. Centrifuge cells at 150 x g for 5 min and carefully discard all of the supernatant.
5. Resuspend cells in a small volume (~100 μ l) of complete RPMI, perform a cell count and adjust to 1×10^6 cells/ml.
6. Pipette 1 ml of cells into the wells of a 48 well plate. Pipette 1 ml of DPBS into any unoccupied wells to obtain more reproducible results.
7. Incubate at 37 °C in 5% CO₂ in air for desired timepoints, here 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hr. Note: The length of time will depend on what the experimental design aims to measure.
8. Transfer all the cells into FACS tubes using a pipette. Rinse the well sequentially with 1 ml volumes of PBS to a final total volume of 5 ml.
9. Centrifuge at 150 x g for 5 min and carefully remove all the supernatant. Cells are ready for staining, perform this (section 4) immediately.

4. Cell Staining

Note: If surface staining of cells is required perform it prior to fixation, ensuring that the cells are kept at 4 °C throughout.

1. Resuspend cells in 100 µl of staining buffer (for optional surface staining, add the recommended volume of antibody to surface antigens and incubate for 30 min at 4 °C).
2. Add 1 ml of staining buffer, centrifuge for 5 min at 150 x g and discard the supernatant.
Note: Specific antibody, concentration, incubation time *etc.* will vary depending on specific experimental goals.
3. Fixation and Permeabilization
 1. Resuspend cells in 100 µl of fixation buffer and incubate for 15 min at room temperature.
 2. Add 1 ml of wash buffer, centrifuge for 5 min at 150 x g and discard the supernatant.
 3. Resuspend cells in 100 µl of permeabilization buffer and incubate the cells for 10 min on ice.
 4. Add 1 ml of wash buffer, centrifuge for 5 min at 150 x g, and discard the supernatant.
 5. Resuspend cells in 100 µl of fixation buffer per tube and incubate for 5 min at room temperature.
 6. Add 1 ml of wash buffer, centrifuge for 5 min at 150 x g, and discard the supernatant.
Note: The protocol can be paused here if required. The fixed cells are stable for several days at 4 °C if resuspended in staining buffer. Remove the staining buffer following centrifugation before proceeding.
4. DNase Treatment
 1. Resuspend cells in 100 µl of DNase solution (30 µg of DNase/10⁶ cells) and incubate cells for 1 hr at 37 °C.
 2. Add 1 ml of wash buffer, centrifuge at 150 x g for 5 min and discard supernatant.
5. Antibody Staining
Note: Staining for intracellular markers other than BrdU can be performed simultaneously with the BrdU staining.
 1. IMPORTANT: Prepare compensation controls consisting of unstained cells and cells labeled with each single fluorochrome. Ideally, use the same antibodies for compensation controls as those used in the experimental tubes. However, if this is not feasible, substitute antibodies to highly expressed antigens conjugated to the same fluorochrome.
 2. Resuspend the cells in 50 µl of wash buffer and add 1 µl/10⁶ cells of BrdU antibody. Note: Directly conjugated antibodies to other specific intracellular antigens can also be added.
NOTE: Antibodies to histone H3 phosphorylated on Ser10 can be used to discriminate between cells in G2 and M, histone H3 is phosphorylated on Ser10 during mitosis.¹⁰ Antibodies to cdc2 phosphorylated on Tyr15 can be used to detect cells that have committed to mitosis.¹¹
 3. Incubate the cells for 20 min at room temperature.
 4. Add 1 ml of wash buffer, centrifuge cells at 150 x g for 5 min and discard supernatant.
6. Stain DNA for Cell Cycle Analysis
 1. Loosen pellet and add 20 µl of the 7-AAD solution (0.25 µg). Note: It is critical to use a constant amount of 7-AAD/cell.
 2. Resuspend the cells in 1 ml of Staining buffer.

5. Collection of Flow Cytometry Data

Note: The machine required will depend on the number and nature of the fluorochromes used.

1. Collect the following parameters: FSC-A, SSC-A, FSC-H (FSC-W can be used instead of FSC-H) and 7-AAD fluorescence on a linear scale. Collect the APC channel on a log scale. Collect any additional channels required for the assessment of surface or internal labels using a log scale.
2. Perform compensation of overlapping signals in emission spectra observed between different fluorochromes before analyzing the samples.
Note: Most flow cytometers will perform this automatically.
3. Collect at least 10,000 events for each sample.

6. Analysis of Flow Cytometry Data

Note: FlowJo was used in this study for flow cytometry data analysis but other software packages can also be used. The gating strategy is illustrated in **Figure 1**.

1. Identify the viable cell population using FSC-A and SSC-A parameters.
2. Within this population exclude doublets and aggregates using FSC-A and FSC-H (FSC-W can also be used here).
3. Within this population set a dot plot using 7-AAD on the x-axis and BrdU-APC on the y-axis.

Figure 1: Gating Strategy. Left panel: ungated cells are shown on a FCS-A vs. SSC-A dot plot. The viable cell population is identified by the gate shown. Center panel: cells gated from the left panel are shown on a FSC-A vs. FSC-H dot plot (FSC-W can be used instead of height). Doublets and aggregates are identified, and excluded by the gate shown. Right panel: cells gated from the doublet exclusion date in the center panel are shown on a 7-AAD vs. APC-A dot plot. The BrdU antibody is labeled with APC permitting the identification of cells that have incorporated BrdU during the pulse labeling. 7-AAD provides information on DNA content. The upper gate defines cells positive for BrdU and therefore in S phase at the time of the BrdU pulse, the lower left gate, cells in $G_{0/1}$ and the lower right gate those in G_2/M . [Please click here to view a larger version of this figure.](#)

4. Cell Cycle Analysis

1. Open the first data file and gate on the cells in the doublet exclusion gate.
2. Analyze this population for cell cycle distribution (located under platforms in FloJo software) and use the Dean-Jett-Fox model.
3. Obtain the positions of the $G_{0/1}$ and G_2/M peaks using create gates.
4. Gate on the BrdU positive cells and subject this population to same cell cycle analysis.
5. Provide the positions for the $G_{0/1}$ and G_2/M peaks by applying the same gates from create gates and setting constraints (using the created gates) for the positions of the $G_{0/1}$ and G_2/M peaks. This is illustrated in the first 2 panels of **Figure 2**.

Note: Other software may also be used to analyze the data and the instructions would vary accordingly.

Figure 2: Cell Cycle Progression. The first panel (All Cells) is gated on the cell population defined by the doublet exclusion gate. This population was displayed in a histogram with 7-AAD on the X-axis. The peak of the G₀/1 peak is indicated by the arrow below the axis. In subsequent panels BrdU positive cells have been gated on as shown in **Figure 1**. The value for the G₀/1 position obtained when gating of the doublet exclusion gate is applied to the BrdU positive gated cells within FlowJo cell cycle software. Each subsequent panel was gated on the BrdU positive population as shown in **Figure 1** and the position of the G₀/1 peak based on the value obtained when analyzing the whole population as shown in the first two panels. Using the BrdU negative fraction to identify the location of the G₀/1 population for the BrdU positive cells in the same sample controls for any slight differences in the intensity of the DNA stain between samples. The number shown on each panel represents the time since the BrdU pulse ended. The calculated cell cycle phases are shown in shaded green. [Please click here to view a larger version of this figure.](#)

Representative Results

This methodology can be used to obtain a range of information. A few applications are outlined here.

Assessment of the duration of the cell cycle

To determine the time required for cells to transit through the cell cycle, cells are harvested at various time points following the BrdU pulse. The intervals between assessments can be adapted to the particular cells being analyzed. Hematopoietic cell lines were assessed every hour over a 24 hr period in the absence of any drug treatment to determine the length of cell cycle phases under standard culture conditions. **Figure 2** shows a selection of snapshot analysis of NALM6 cells over a 24 hr period. The cells in S phase at the time of the BrdU pulse (*i.e.* within the BrdU positive gate in **Figure 1**) progressed through G₂/M, with a peak of cells in that phase of the cell cycle being detected 10 hr after the BrdU pulse. The proportion of BrdU labeled cells in S phase reached its nadir 14 hr after the pulse and almost all cells had returned to G₁ after 17 hr. By 24 hr a proportion of the BrdU labeled cells had reentered S phase as part of their next cell cycle indicating that cells can complete a cell cycle within 24 hr, however most had not yet entered a second round of replication, consistent with the known 36 hr doubling time for these cells.

Cell cycle distribution can be further refined by the inclusion of additional markers. For example, the addition of an antibody to histone H3 phosphorylated on Ser10 (a marker of cells in mitosis) permits the discrimination of cells in mitosis from those in G₂ (left panels of **Figure 3**).

Figure 3: Confirmation of Cell Cycle Stage Using Additional Markers. The upper panels show the cell cycle analysis of cells from the BrdU positive gate as shown in **Figure 1**. The cells had been incubated in the presence or absence of 3 nM vincristine for 18 hr after the BrdU pulse. The cell cycle analysis was conducted as described in **Figure 2**. The lower panels show the same cells on 7-AAD vs. Histone H3 phosphorylated on Ser10 dot plot. [Please click here to view a larger version of this figure.](#)

Assessment of Drug Effects on the Cell Cycle

Cytotoxic agents can have profound effects on cell cycle progress and can induce cell death. The effect of drugs on cell cycle progression can be assessed by adding the drugs of interest following the BrdU pulse. Two examples are shown. The first was a situation where the induction of

cell death confounded the analysis of cell cycle data (right panels of **Figure 3**). NALM6 cells had been exposed to 3 nM vincristine for 18 hours after the BrdU pulse. Cells were expected to arrest in mitosis as vincristine targets microtubules. However the cell cycle analysis suggested that the cells had not arrested but transited through to $G_{0/1}$ (**Figure 3** upper right panel). The addition of an antibody to histone H3 phosphorylated on Ser10 showed that cells had not exited mitosis (**Figure 3** lower right panel), despite having a reduced DNA content. It is likely that the DNA content was decreased because the cells were undergoing apoptosis and had started to degrade their DNA. Since the cells initiated apoptosis while in mitosis (*i.e.* with 4N DNA), they appear as S phase or $G_{0/1}$ cells instead of the typical apoptotic sub- G_1 peak.

Figure 4: Detection of Cell Cycle Stage Specific Killing. The dot plots show the percentage of BrdU positive cells remaining in the culture 24 hr after the BrdU pulse. Cells had been cultured in the presence or absence of vehicle alone (Control), 1.5 or 16 μ M RAD001 since the end of the BrdU pulse. The lower panel shows the percentage of cells that were BrdU positive over the 24 hr incubation. [Please click here to view a larger version of this figure.](#)

In another example, **Figure 4** shows how in the presence of a low concentration of RAD001 (an mTOR inhibitor) cells were able to complete the cell cycle but then underwent a delay or arrest in $G_{0/1}$. A higher concentration of RAD001 largely prevented cells from transiting through to $G_{0/1}$. Importantly cells in S phase (*i.e.* BrdU positive) were shown to preferentially disappear from the culture when RAD001 was added. This suggests that cells passing through G_2/M were more susceptible to cell death by this agent.¹²

It is also possible to examine responses of cells in particular phases of the cell cycle using antibodies to specific antigens. In **Figure 5** the activation of the cell cycle checkpoint controlling proteins Chk1 and Chk2 in response to vincristine treatment is shown. Chk1 and Chk2 are activated by phosphorylation on Ser345 and Thr68 respectively. Activation of Chk1 and Chk2 can be seen in cells that appear to have a 2N DNA content but as shown in **Figure 5** are likely to be cells in mitosis that have commenced DNA degradation as a result of apoptosis.

It is possible to add drugs at various time points after the BrdU pulse to examine the effect of the agent on cells at various stages of the cell cycle.

Figure 5: Detection of Changes to Cells in Particular Cell Cycle Phases. The upper panel shows cells gated on the BrdU positive cells as in Figure 1 in 7-AAD vs. phosphorylated Chk1 (left) or Chk2 (right) dot plots. The cells had been culture for 18 hr following the BrdU pulse in the presence or absence of 3 nM vincristine as for Figure 3. The lower panels show overlay histograms of the same cells gated on either the 2N or 4N fraction as indicated. [Please click here to view a larger version of this figure.](#)

Discussion

The ability to analyze the cell cycle is important for the understanding of cancer biology and the mechanism of action of both drugs and genes that influence cell proliferation and growth. While there are a multitude of assays that reportedly measure cell proliferation, the majority only provide a measure that indicates the number cells present. These include assays that measure cell number by direct visualization and counting, metabolic activity or ATP concentration. The main advantage of many of these methods is that they are relatively easy to perform and amenable to microplate formats and automation, making them useful for screening large numbers of conditions or compounds. A shortcoming of many of these methods is that cell loss due to death is not taken into consideration, potentially leading to an underestimate of cell proliferation. Also these methods measure the bulk population and do not permit the study of single cells or the transit of cells through the cell cycle.

Of the commonly used proliferation assays, perhaps the most reliable and accurate are those that measure DNA synthesis. Traditional cell proliferation assays incubate cells for a few hours to overnight with ^3H -thymidine, which is incorporated into newly synthesized DNA.¹³ The obvious problem with this method is the use of radioactive materials, but another limitation is that the result measures the average proliferation of a population of cells. BrdU can be similarly used without the radiation issues, although additional steps are required and BrdU is a potential mutagen. However, BrdU has the advantage of being compatible with flow cytometry, permitting the analysis of single cells.¹⁴ Other flow cytometry compatible methods for assessing cell proliferation at the single cell level include a growing number of dyes that label the cell membrane or cellular proteins (e.g. CFSE) that divide between daughter cells, DNA intercalating dyes and cell cycle specific antigen detection by antibodies. The best of cell labeling dyes permit cell division tracking over a number of cell divisions.¹⁵ They provide a direct measure of proliferation, although no information about cell cycle stage or distribution is obtained. The measurement of DNA content using DNA intercalating dyes such as propidium iodide or 7-AAD provide strong cell cycle distribution¹⁶, but not temporal, data. Even with the assessment of multiple time points it remains impossible to assess the length of the cell cycle or specific cell cycle phases. Cell cycle specific antigens can be used to assess cell cycle phase in an unsynchronized cell population. Commonly used cell cycle specific antigens include Ki-67,¹⁷ which is expressed during the S, G₂ and M phases of the cell cycle but not during G_{0/1}, PCNA (proliferating cell nuclear antigen)¹⁸, and phosphorylation of histone H3.¹⁹ While these provide good data regarding the cell cycle stage, information relating cell cycle dynamics is lacking.

Obtaining data on cell cycle dynamics has traditionally been examined by synchronizing cells using agents or culture conditions that block cell cycle progression. This causes an accumulation of cells behind the block, that once removed, result in wave of cells progressing together through the cell cycle.¹ The calculation of the duration of the cell cycle and the length of the various cell cycle phases is then possible. Cells can be induced to exit active cell cycling entering G₀ by serum deprivation. Upon the re-addition of serum the cells may then move together into subsequent phases.²⁰ While this is a reliable method for certain cell types, others, including many transformed cell types, fail to exit the cell cycle and frequently undergo cell death as a result.²¹ Indeed our studies found this to be the situation for acute lymphoblastic leukemia cells. Furthermore, cells will often fail to reenter cell cycle in a sufficiently synchronized manner. Chemical methods can be used to induce cell cycle arrest at specific phases of the cell cycle. For example, agents that prevent DNA synthesis (e.g. excess thymidine) or prevent the mitotic spindle formation (e.g. nocodazole) arrest cells in S and M phases respectively, but are toxic and can result in growth disturbances and even death in a significant proportion of the cells.²² In ALL cells these methods failed to arrest the majority of cells without killing a significant fraction. Considering that the aim was to assess the effects of a potential anti-leukemic agent on cell cycle parameters, the cell death resulting from synchronization was unacceptable. Despite the description of a large number of methods to synchronize cells, all have shortcomings. The main problems are: an insufficient enrichment for cells in the desired part of the cell cycle, disturbances to the normal physiology of the cell cycle or, as observed, excess toxicity.

The method described here is a simple extension of the long used pulse system, where cells are incubated for a brief period with BrdU to identify cells in S phase. We found a 45 min pulse to be optimal in our system but shorter time periods may be used if sufficient labeling is obtained. By continuing to culture cells after the removal of the BrdU it is possible to track their progression through the remainder of S phase, G₂, mitosis, G₁ and entry into the next cell cycle. It may be possible to follow the cells further. The advantage of this system is that there is no evidence of toxicity to the cells in the time frame of these experiments and there is minimal disruption to the growth of the cells, as only a couple of media changes are required. The cells are otherwise maintained in continuous culture. The flow cytometry based nature of the method means that it can be combined with the identification of cell subpopulations by additional surface or intracellular staining. We used APC conjugated BrdU antibodies but other conjugates can be substituted to facilitate the development of antibody panels. We used 7-AAD rather than propidium iodide because 7-AAD fluoresces in a single channel maximizing options for multicolor staining. Similarly DAPI or Hoechst can be used as DNA stains but require a UV laser. Tighter CVs for DNA staining can be obtained using ethanol fixation but this frequently compromises antibody staining, limiting the options for additional surface or cytoplasmic stains. The biggest disadvantage is that S phase lasts about 8 hr, so labeled cells may have just entered or about to exit S phase during the pulse period. As a result, the synchronization is not as tight as with some other systems. However, by combining the BrdU labeling with dyes indicating DNA content and antibodies to specific cell cycle dependent proteins, strong data can be obtained.

In order to obtain consistent data it is important to ensure that cells are at the correct concentration and that the cell concentration is consistent across all the conditions being compared. Critically the brightness of the 7-AAD staining is very sensitive to cell concentration. Using an automated cell counting system can help ensure that cell concentrations are consistent in all samples at each step in the process. Another important point is the length of time the cells are exposed to BrdU. Small variations can translate into considerable differences, so it is important that all samples are incubated with BrdU for precisely the same time. Finally, it is important to titrate antibodies to obtain optimal staining and this should be repeated whenever a batch is changed. If all the steps are followed consistently and cell concentrations kept constant then this method will reliably enable the tracking of cells through the cell cycle without the need for synchronization. There is also considerable scope to modify this method to suit particular cell types and address specific questions.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The work was funded by the Leukemia and Lymphoma Society of the USA (6105-08), a Cancer Council NSW grant (13-02), an NHMRC Senior Research Fellowship (LJB) (1042305) and project grant (1041614).

References

1. Banfalvi, G. *Methods Mol Biol.* Banfalvi, G. **761**, 1-23 Humana Press New York, Dordrecht, Heidelberg, London (2011).
2. Sakaue-Sawano, A., *et al.* Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. *Cell*. **132**, 487-498 (2008).
3. Harper, J. W., Elledge, S. J. The DNA damage response: ten years after. *Molecular Cell*. **28**, 739-745 (2007).
4. Latt, S. A., George, Y. S., Gray, J. W. Flow cytometric analysis of bromodeoxyuridine-substituted cells stained with 33258 Hoechst. *The Journal of Histochemistry and Cytochemistry*. **25**, 927-934 (1977).
5. Gratzner, H. G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. *Science*. **218**, 474-475 (1982).
6. Carayon, P., Bord, A. Identification of DNA-replicating lymphocyte subsets using a new method to label the bromo-deoxyuridine incorporated into the DNA. *Journal of Immunological Methods*. **147**, 225-230 (1992).
7. Gonchoroff, N. J., *et al.* S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. *Journal of Immunological Methods*. **93**, 97-101 (1986).
8. Rabinovitch, P. S., Torres, R. M., Engel, D. Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-amino-actinomycin D and single laser excitation: applications to study of cell activation and the cell cycle of murine Ly-1 B cells. *Journal of Immunology*. **136**, 2769-2775 (1986).
9. Saunders, P. O., *et al.* RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine. *Oncogene*. **32**, 4789-4797 (2013).

10. Hendzel, M. J., *et al.* Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. *Chromosoma*. **106**, 348-360 (1997).
11. Draetta, G., Beach, D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. *Cell*. **54**, 17-26 (1988).
12. Saunders, P. O., *et al.* RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine. *Oncogene*. (2012).
13. Knudsen, R. C., Ahmed, A. A., Sell, K. W. An in vitro microassay for lymphotoxin using microculture plates and the multiple automated sample harvester. *Journal of Immunological Methods*. **5**, 55-63 (1974).
14. Beck, H. P. Proliferation kinetics of perturbed cell populations determined by the bromodeoxyuridine-33258 technique: radiotoxic effects of incorporated [3H]thymidine. *Cytometry*. **2**, 170-174 (1981).
15. Miller, M. J., Wei, S. H., Parker, I., Cahalan, M. D. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. *Science*. **296**, 1869-1873 (2002).
16. Collins, J. M., Berry, D. E., Bagwell, C. B. Different rates of DNA synthesis during the S phase of log phase HeLa S3, WI-38, and 2RA cells. *Journal of Biological Chemistry*. **255**, 3585-3590 (1980).
17. Schwarting, R., Gerdes, J., Niehus, J., Jaeschke, L., Stein, H. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. *Journal of Immunological Methods*. **90**, 65-70 (1986).
18. Danova, M., *et al.* Cell cycle-related proteins: a flow cytofluorometric study in human tumors. *Biology of the Cell*. **64**, 23-28 (1988).
19. Juan, G., *et al.* Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. *Cytometry*. **32**, 71-77 (1998).
20. Langan, T. J., Chou, R. C. Synchronization of mammalian cell cultures by serum deprivation. *Methods in Molecular Biology*. **761**, 75-83 (2011).
21. Kues, W. A., *et al.* Cell cycle synchronization of porcine fetal fibroblasts: effects of serum deprivation and reversible cell cycle inhibitors. *Biology of Reproduction*. **62**, 412-419 (2000).
22. Urbani, L., Sherwood, S. W., Schimke, R. T. Dissociation of nuclear and cytoplasmic cell cycle progression by drugs employed in cell synchronization. *Experimental Cell Research*. **219**, 159-168 (1995).